Design Therapeutics, Inc.
NASDAQDesign Therapeutics entered this week with one of the more confusing setups in small-cap biotech: clinical data that showed clear biological activity, and a stock that promptly fell more than a third. The proximate cause was Monday's readout from the RESTORE-FA Phase I/II trial of DT-216P2 in Friedreich Ataxia. Four weeks of IV dosing produced dose-dependent frataxin increases and…
Snapshot as of 22 Jun 2026
Design Therapeutics entered this week with one of the more confusing setups in small-cap biotech: clinical data that showed clear biological activity, and a stock that promptly fell more than a third. The proximate…
Design Therapeutics arrives at its May 8 Q2 earnings call on a genuine high. The stock jumped 23% on April 28 after Q1 EPS of -$0.29 beat estimates by $0.05 and the company narrowed its net loss. It has since pulled…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DSGN — free to start on ORTEX.
Sign up for free →Open DSGN on ORTEX